WE ARE REFLEXION
ABOUT
REVOLUTIONIZING PROTEIN THERAPEUTICS
We are a passionate group of scientists engaged in groundbreaking translational research. Reflexion Pharmaceuticals is developing a revolutionary new class of protein-based therapeutics that overcome the limitations of current biologics. By engineering enantiomeric proteins composed entirely of D-peptides, we are creating new drug entities that are non-immunogenic and inherently resistant to proteolysis, vastly improving pharmacokinetics. Our game-changing platform technology allows us to pursue virtually any disease target and shows limitless potential.
Â
Â
TECH
ENGINEERING MIRROR-IMAGE MEDICINE
We use a technique called mirror-image phage display to engineer synthetic D-protein therapies against a broad range of disease targets. After we identify our target protein in its naturally occurring L-form, we chemically synthesize its mirror-image enantiomer using D-amino acids. We then use several rounds of phage display to evolve high-affinity binding variants against this mirror-image of the disease target. Finally, we chemically synthesize these binders as D-proteins that act as highly potent antagonists to the disease targets in vivo.
ADVANTAGES


SMALL SIZE
Our proprietary D-proteins are 30X smaller than antibody therapeutics enabling better tissue and tumor penetration, while allowing scalable chemical manufacturing as well as flexible formulation and dosing strategies without sacrificing affinity


RESISTANT TO PROTEOLYSIS
Because our therapeutics are chemically synthesized of D-amino acids, they are resistant to degradation by proteases, increasing their half-life in the tumor microenvironment and allowing for superior pharmacokinetics compared to other drugs


NON-IMMUNOGENIC
D-proteins are not proteolytically cleaved so they avoid MHC presentation, rendering them invisible to the adaptive immune system and preventing the development of Anti-Drug Antibodies (ADAs), a significant problem with antibody therapeutics


BBB PENETRATION
Our D-proteins can effectively penetrate the Blood-Brain Barrier, allowing us to engage a trove of targets within the brain not accessible to any conventional antibody-based drugs

Â
OUR THERAPEUTIC PIPELINE
ASSETS
Â
TEAM
WHO WE ARE
DANA AULT-RICHE, PHD
CEO
PAUL STEPHEN MARINEC, PHD
Senior Scientist
KYLE LANDGRAF, PHD
Senior Scientist
STEPHEN KENT, PHD
Scientific Co-Founder
SACHDEV SIDHU, PHD
Scientific Co-Founder
RICHARD VAN DEN BROEK, CFA
Board Director
Â